<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - VARDENAFIL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>VARDENAFIL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Erectile dysfunction</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using orodispersible tablet</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 mg (max. per dose 20 mg), to be taken approximately 25&#8211;60 minutes before sexual activity, subsequent doses adjusted according to response, onset of effect may be delayed if taken with high-fat meal; maximum 1 dose per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg, to be taken approximately 25&#8211;60 minutes before sexual activity; maximum 10 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Erectile dysfunction (patients on alpha-blocker therapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using tablets</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg (max. per dose 20 mg), to be taken approximately 25&#8211;60minutes before sexual activity, subsequent doses adjusted according to response, onset of effect may be delayed if taken with high-fat meal; maximum 1 dose per day.</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Concomitant treatment with phosphodiesterase type-5 inhibitor and an alpha-blocker can increase the risk of postural hypotension&#8212;initiate treatment with a phosphodiesterase type-5 inhibitor (at a low dose) only once the patient is stable on the alpha-blocker.</p>
            </section>
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>
            <i>Levitra<tm tmtype="reg"/> 10 mg orodispersible tablets</i> and <i>Levitra<tm tmtype="reg"/> 10 mg film coated tablets</i> are <b>not</b> bioequivalent.</p>
            </section>
        
        
        
      </section>




      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Initial dose 5&#8239;mg in mild to moderate impairment, increased subsequently according to response (max. 10&#8239;mg in moderate impairment).</p>
            </section>
            <section class="generalInformation">
              <p>Manufacturer advises avoid in severe impairment.</p>
            </section>
            <section class="generalInformation">
              <p>Orodispersible tablets not suitable for patients with moderate hepatic impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Initial dose 5&#8239;mg if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2.</sup>
            </p>
            </section>
        
            <section class="generalInformation">
              <p>Orodispersible tablets not suitable if eGFR less than 30&#8239;mL/minute/ 1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid if systolic blood pressure below 90 mmHg</li>
            <li>hereditary degenerative retinal disorders</li>
            <li>myocardial infarction</li>
            <li>patients in whom vasodilation or sexual activity are inadvisable</li>
            <li>previous history of non-arteritic anterior ischaemic optic neuropathy</li>
            <li>recent stroke</li>
            <li>unstable angina</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Back pain, dizziness, dyspepsia, flushing, headache, migraine, myalgia, nasal congestion, nausea, visual disturbances, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Drowsiness, dyspnoea, epistaxis, hypertension, hypotension, increased lacrimation, painful red eyes, palpitation, photosensitivity, tachycardia,
              </p>
              <p>
                <strong>rare:</strong> Anxiety, facial oedema, hypersensitivity reactions, hypertonia, priapism, raised intra-ocular pressure, rash, Stevens-Johnson syndrome, syncope, transient amnesia,
              </p>
              <p>
                <strong>notKnown:</strong> Arrhythmia, myocardial infarction, non-arteritic anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs), retinal vascular occlusion, seizures, serious cardiovascular events, sudden hearing loss (discontinue drug and seek medical advice), unstable angina,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active peptic ulceration
          </li>
          <li>
            anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie&#8217;s disease)
          </li>
          <li>
            bleeding disorders
          </li>
          <li>
            cardiovascular disease
          </li>
          <li>
            elderly
          </li>
          <li>
            left ventricular outflow obstruction
          </li>
          <li>
            predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia)
          </li>
          <li>
            susceptibility to prolongation of QT interval
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Orodispersible tablets not suitable for initiation of therapy in patients taking alpha-blockers.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of VARDENAFIL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76603"><a href="../medicinalForm/PHP76603.html" data-target="#PHP76603" data-action="load">Tablet</a></div>
            <div id="PHP76611"><a href="../medicinalForm/PHP76611.html" data-target="#PHP76611" data-action="load">Orodispersible tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
